Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: A clinicopathological analysis

Anti-Cancer Drugs

Volumn 19, Issue 6, 2008, Pages 607-612

  Mearadji, Amir ^a   Den Bakker, Michael A ^a   Van Geel, Albertus N ^a   Eggermont, Alexander M M ^a   Sleijfer, Stefan ^a   Verweij, Jaap ^a   De Wilt, Johannes H W ^a   Verhoef, Cornelis ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CD117; Gastrointestinal stromal tumors; Imatinib; Induction therapy; Pathology; Resection

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; INOPERABLE CANCER; MALE; METASTASIS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; CHEMISTRY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TUMOR MARKERS, BIOLOGICAL;

EID: 53749088452     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32830138f9     Document Type: Article

References (26)

1. Graadt van Roggen JF, van Veldhuysen ML, Hoogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 2001; 54:96-102.
2. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33:459-465.
3. Joensuu H, Kindblom LG. Gastrointestinal stromal tumors: a review. Acta Orthop Scand Suppl 2004; 75:62-71.
4. Miettinen H, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Human Pathol 2002; 33:478-483.
5. Sarloma-Rikal M, Kovatich AJ, Barusevicius A, Miettinen M. CD 117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11:728-734.
6. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152:1259-1269.
7. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al.Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127-1134.
8. Demetri GD, von Mehren M, Blanke CD, van den Abbeele AD, Eisenberg B, Roberts PJ, et al.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stroma tumors. N Engl J Med 2002; 347:472-480.
9. DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245:347-352.
10. Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007; 245: 341-346.
11. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, et al. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 2007; 13: 170-181.
12. Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz B, et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 2006; 14:526-532.
13. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11:4182-4190.
14. Therasse P, LeCesne A, van Glabbeke M,Verweij J, Judson I. RECIST versus WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer 2205; 41:1426-1430.
15. Fujimoti Y, Nakamischi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003; 6:39-48.
16. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002; 38: S37-S38.
17. Bucher P, Egger J-F, Gervaz P, Ris F, Weintraub D, Villiger P, et al. An audit of surgical management of gastrointestinal stromal tumours (GIST). Eur J Surg Oncol 2006; 32:310-314.
18. Benjamin RS, Blanke CD, Blay JY, Bonvalot S, Eisenberg B. Management of gastrointestinal stromal tumours in the imatinib era: selected case studies. Oncologist 2006; 11:9-20.
19. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14:14-24.
20. Bonvalot S, Eldweny H, Pechoux CL, Vanel D, Terrier P, Cavalcanti A, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006; 13:1596-1603.
21. Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24:2325-2331.
22. Rutkowski P, Nowecki Z, Nyckowski P, Dziewieski W, Grzesiakowska U, Nasierowska-Guttmejer A, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93:304-311.
23. van Glabbeke M, Verweij J, Casali PG, LeCesne A, Hohenberg P, Ray-Coquard I, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23:5795-5804.
24. Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2001; 2:485-491.
25. Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Cin Oncol 2007; 25:1107-1113.
26. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006; 30:477-489.